Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017;…
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit…
Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European…
Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon…
Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in neonatology and strength respiratory franchise in…
See our Cookie Privacy Policy Here
